Navigation Links
Oramed Granted Canadian Patent for GLP-1 Analog Capsule
Date:5/9/2017

JERUSALEM, May 9, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed a patent titled, "Methods and Compositions for Oral Administration of Exenatide". The patent covers Oramed's invention of an oral glucagon-like peptide-1 (GLP-1) analog.

GLP-1 is an incretin hormone that stimulates the secretion of insulin from the pancreas. Exenatide, a GLP-1 analog, is currently marketed in injectable form only, and is indicated for treatment of type 2 diabetes. Exenatide induces insulin release at increased glucose levels and causes a feeling of satiety, which results in reduced food intake and weight loss.

Oramed's oral GLP-1 capsule based on the Company's Protein Oral Delivery (PODTM) technology could significantly increase compliance and become a valuable tool in the treatment of diabetes.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's PODTM technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801).  The Company completed multiple Phase II clinical trials of ORMD-0801 under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit www.oramed.com.

Forward-looking statements:  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our GLP-1 capsule increasing compliance and becoming a valuable tool in the treatment of diabetes, as well as when we discuss revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Estee Yaari
+1-877-9-ORAMED
Email: estee@oramed.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oramed-granted-canadian-patent-for-glp-1-analog-capsule-300454015.html


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Oramed to Present at the American Diabetes Association 76th Scientific Sessions
2. Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study
3. Oramed to Present at Oppenheimer Annual Israeli Conference
4. Oramed Patent Being Granted in China for Oral Administration of Proteins
5. Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar
6. Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent
7. Oramed Completes Phase IIb Oral Insulin Study
8. Oramed Patent Granted in India for Oral Administration of Proteins
9. Oramed Pharmaceuticals Shareholder Letter
10. Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China
11. Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
(Date:5/4/2017)... May 4, 2017  A recent study published ... Ultraviolet-C light as a means of disinfection ... to reduce bioburden on anesthesia workstations. In the ... high-touch, complex medical equipment surfaces contaminated with three ... "This study further validates the body of ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... 2017 , ... Patients who want to receive cosmetic dentistry procedures such as ... Bedich for a consultation, with or without a referral. Dr. Bedich enjoys improving the ... , Dr. Bedich offers a variety of cosmetic dentistry services at his practice ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... recently completed Course II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) ... learning the latest advancements in his field by attending numerous CE courses each ...
(Date:5/24/2017)... ... May 24, 2017 , ... Accordant Technology, a trusted ... ExtraHop delivers an analytics-first approach, layered with machine learning, that provides real-time visibility ... to the cloud to the edge. Through the new partnership, customers get the ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Rob Lowe is ... “Informed,” developed for Public Television. “Informed” brings the public important topics from all aspects ... treatment of the feet and issues surrounding feet and ankles. , Podiatry is essential ...
(Date:5/24/2017)... ... 24, 2017 , ... Technique, technique, technique – with a dash of common ... strength training and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional ... Dr. Chang says. “Improper technique in lifting anything heavy or an attempt to lift ...
Breaking Medicine News(10 mins):